Sonde Health, Inc.

Sonde Health, Inc. , based in the US, specializes in a vocal biomarker platform that enhances mental, cognitive, and respiratory health through innovative voice-enabled applications. Founded in 2015 and headquartered in Boston, US, Sonde Health, Inc. develops a vocal biomarker analysis platform for health monitoring.

The company has completed 2 deals, with its latest funding round being a Series B in December 2022, raising USD 19. 25 mn led by Partners Investment, with participation from KT Corporation, M Ventures, NEOM Investment Fund, and PureTech Health plc. The total raised to date is USD 19. 25 mn, resulting in a current valuation of USD 73.

423 mn. The company’s CEO is David Liu, and it was established by James Harper. Sonde Health's primary offering is a clinically validated vocal biomarker platform designed to enhance mental, cognitive, and respiratory health outcomes through voice-enabled applications and devices. The platform utilizes advanced machine learning and millions of medically-labeled voice samples to analyze vocal variations, which may signal early health issues comparable to traditional vital signs.

The end use cases aim to facilitate early detection of health risks, promote employee engagement, reduce burnout and turnover, and maintain a healthy workforce, particularly within blue-collar enterprises. The company's solutions cater primarily to organizations seeking to integrate health initiatives into their existing frameworks, with a focus on improving workforce performance. Sonde Health’s products are designed for markets in North America and Europe, where they serve a diverse clientele, including businesses in various sectors that prioritize employee wellness. Sonde Health generates revenue through strategic partnerships and B2B transactions, primarily by providing subscription-based access to its vocal biomarker analysis platform.

Organizations interested in leveraging this technology typically enter into agreements that allow for the integration of Sonde’s API/SDK into their health initiatives. The pricing structure is tailored to the specific needs of each client, allowing for flexible engagement based on usage and organizational size. Revenue is driven by ongoing subscriptions and possibly additional service fees associated with advanced analytics or tailored support. The company's focus on partnerships indicates a sustained commitment to collaborating with enterprises that value proactive health management and employee wellness.

In December 2022, Sonde Health, Inc. raised USD 19. 25 mn in Series B funding led by Partners Investment, with participation from NEOM and KT Corporation, alongside returning investors M Ventures and PureTech Health plc. The funds will be utilized to accelerate the company’s commercial growth and expand its platform internationally.

Specific plans for product development include enhancing the vocal biomarker technology and exploring new applications in mental and respiratory health. Additionally, Sonde Health aims to penetrate further into European markets while continuing to solidify its presence in North America.